ERBB2 and breast carcinoma: Increased ATP synthesis is also involved in the acquired drug resistance of breast cancer cells to HER-2-targeted antibody therapy, and such resistance can be reversed via the inhibition of ATP synthesis by oligomycin A or knockdown of the ATP synthase complex in resistant cells [102].